ORIC PHARMACEUTICALS, INC. (ORIC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 20.76M USD | Liabilities, Current |
| Cash and equivalents | 37.48M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 227.28M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $20.76M | $37.48M | $227.28M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $17.77M | $56.40M | $225.54M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $20.42M | $45.67M | $235.82M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $20.18M | $49.67M | $237.47M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $18.05M | $75.86M | $206.65M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $17.62M | $49.33M | $154.39M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $24.85M | $59.41M | $196.55M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $21.25M | $44.23M | $228.14M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $19.54M | $49.83M | $236.57M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $15.21M | $56.36M | $260.42M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $20.46M | $23.38M | $184.80M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $18.94M | $26.24M | $201.06M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $14.53M | $103.68M | $160.48M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $14.87M | $58.99M | $130.64M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $15.39M | $66.84M | $139.43M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $13.28M | $29.08M | $164.58M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $12.47M | $49.08M | $177.98M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $11.82M | $112.64M | $121.98M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $15.15M | $226.01M | $10.97M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $11.90M | $241.13M | $48.39M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $9.90M | $170.08M | $90.99M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $7.68M | $104.21M | $173.93M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $9.00M | $78.45M | $215.15M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.93M | $62.03M | $124.58M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $5.78M | $196.64M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $4.78M | $79.44M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $5.35M | $89.16M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |